uploads///Taltz

Eli Lilly’s Immunology Business Saw Solid Growth in 2017

By

Updated

Taltz’s revenue trends

In 4Q17, Eli Lilly’s (LLY) Taltz generated revenues of $172.5 million compared to $61.3 million in 4Q16. In 4Q17, Taltz saw a ~14% growth on a quarter-over-quarter basis.

In 4Q17, in the US market and international markets, Taltz reported revenues of $142.5 million and $30 million, respectively, compared to $59.5 million and $1.8 million, respectively, in 4Q16.

In fiscal 2017, Taltz reported revenues of $559.2 million compared to $113.1 million in 2016. In 2017, in the US market and international markets, Taltz reported revenues of $486 million and $73.2 million, respectively, compared to $110.8 million and $2.3 million, respectively, in 2016.

Article continues below advertisement

Olumiant’s revenue trends

In 4Q17, Eli Lilly’s Olumiant reported revenues of $23 million compared to $16.2 million in 3Q16, which reflected a ~42% growth quarter-over-quarter. In fiscal 2017, Olumiant generated revenues of $45.9 million. Olumiant is used for the treatment of rheumatoid arthritis.

Recent developments

In February 2017, Eli Lilly announced that Taltz met all primary and secondary endpoints in its Phase 3 COAST-V trial. Eli Lilly conducted the Phase 3 COAST-V trial to evaluate the safety and efficacy of Taltz for the treatment of individuals with ankylosing spondylitis. In the trial, Taltz demonstrated statistically significant improvement in reducing the signs and symptoms of ankylosing spondylitis. Eli Lilly plans to submit the pending data of the COAST-V trial for regulatory approval later this year. The label expansion of Taltz is expected to further boost the drug’s revenue growth.

In the psoriatic arthritis and plaque psoriasis drugs market, Taltz competes with Novartis’s (NVS) Cosentyx, Celgene’s (CELG) Otezla, Johnson & Johnson’s (JNJ) Stelara, and AbbVie’s (ABBV) Humira.

Advertisement

More From Market Realist